1. Home
  2. DLO vs ARQT Comparison

DLO vs ARQT Comparison

Compare DLO & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DLocal Limited

DLO

DLocal Limited

HOLD

Current Price

$12.86

Market Cap

3.4B

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$23.69

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLO
ARQT
Founded
2013
2016
Country
Uruguay
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.3B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
DLO
ARQT
Price
$12.86
$23.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
6
Target Price
$17.25
$34.00
AVG Volume (30 Days)
1.7M
1.1M
Earning Date
05-14-2026
05-05-2026
Dividend Yield
1.56%
N/A
EPS Growth
N/A
88.79
EPS
N/A
N/A
Revenue
N/A
$376,072,000.00
Revenue This Year
$26.65
$34.46
Revenue Next Year
$24.48
$29.77
P/E Ratio
$22.27
N/A
Revenue Growth
N/A
91.34
52 Week Low
$7.61
$11.86
52 Week High
$16.78
$31.77

Technical Indicators

Market Signals
Indicator
DLO
ARQT
Relative Strength Index (RSI) 54.55 50.47
Support Level $11.67 $22.56
Resistance Level $13.50 $27.26
Average True Range (ATR) 0.66 0.95
MACD 0.11 0.28
Stochastic Oscillator 72.86 74.71

Price Performance

Historical Comparison
DLO
ARQT

About DLO DLocal Limited

DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company's geographical segments include Latin America and Non-Latin America with a majority of its revenue being generated from Brazil in Latin America region.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: